+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Tract Infection Therapeutic Market by Therapeutic Type, Infection Type, Route Of Administration, Patient Type, Distribution Channel - Global Forecast to 2030- Product Image
Respiratory Tract Infection Therapeutic Market by Therapeutic Type, Infection Type, Route Of Administration, Patient Type, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Respiratory Tract Infection Therapeutic Market by Therapeutic Type, Infection Type, Route Of Administration, Patient Type, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012375
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Tract Infection Therapeutic Market grew from USD 48.43 billion in 2024 to USD 51.85 billion in 2025. It is expected to continue growing at a CAGR of 7.23%, reaching USD 73.64 billion by 2030.

Setting the Stage for Respiratory Tract Infection Therapeutics

Respiratory tract infections remain a persistent threat to global health, imposing significant clinical and economic burdens. The broad spectrum of infectious agents, from bacteria and viruses to inflammatory triggers, demands a multifaceted therapeutic approach. In recent years, heightened awareness of antimicrobial stewardship and emerging viral challenges has underscored the critical need for innovative solutions. This report sets the stage by examining the current landscape, illuminating key drivers and obstacles that shape treatment paradigms. By contextualizing the interplay between evolving pathogen profiles, regulatory shifts, and patient expectations, it offers a foundational lens through which to explore transformative opportunities in the market.

Evolving Dynamics Redefining Respiratory Infection Treatment

The therapeutic landscape for respiratory tract infections has undergone a profound transformation. Innovations in molecular biology have fueled the development of targeted antivirals, while novel delivery systems, such as advanced nebulization technologies, have enhanced drug efficacy and patient adherence. Simultaneously, mounting concerns over antibiotic resistance have accelerated research into non-traditional antimicrobials and host-directed therapies. Digital health platforms and remote monitoring tools now integrate real-time data into treatment protocols, enabling personalized care pathways that adapt to individual risk profiles. Coupled with a heightened focus on value-based healthcare, these shifts are reshaping clinical practice, driving manufacturers and healthcare providers to embrace agile strategies that align with emergent therapeutic trends.

US Tariff Reforms Reshaping Therapeutic Supply Chains

Recent tariff reforms enacted in 2025 have introduced new complexities to pharmaceutical supply chains. Increased duties on active pharmaceutical ingredients and finished drug imports have elevated production costs, squeezing margins for manufacturers reliant on global sourcing. In response, several organizations have accelerated reshoring initiatives, investing in domestic API synthesis and local manufacturing partnerships to mitigate exposure to tariff volatility. These adjustments have ripple effects throughout distribution networks, prompting wholesalers and pharmacies to reevaluate procurement strategies. At the same time, renegotiated trade agreements and tariff waivers for essential medicines are fostering pockets of relief, enabling more stable market access under specific regulatory conditions. Ultimately, these cumulative impacts underscore the necessity for proactive supply chain diversification and strategic sourcing decisions.

Deep Dive into Market Segmentation for Treatment Categories

Understanding the market requires a granular lens on each therapeutic segment. Traditional antibiotics encompass fluoroquinolones, macrolides, penicillins, and tetracyclines, with each subclass addressing distinct bacterial profiles and resistance challenges; antivial agents now target a growing array of respiratory viruses, reflecting advances in polymerase and protease inhibition mechanisms. Cough suppressants range from dextromethorphan-based formulations to novel peripherally acting compounds designed to minimize central nervous system effects, while nasal decongestants balance rapid vasoconstriction with safety profiles suited for extended use. Non-steroidal anti-inflammatory drugs continue to play a supportive role in symptom management, leveraging refined delivery modes to reduce systemic exposure. Infection type further divides the market into lower respiratory tract infections such as bronchitis, pneumonia, and tuberculosis, alongside upper respiratory conditions including laryngitis, pharyngitis, and tonsillitis; each category presents unique therapeutic demands and differentiated treatment algorithms that align with disease severity and patient demographics. Delivery modalities offer yet another dimension: inhalation therapies delivered via metered dose inhalers or nebulizers are critical for targeted pulmonary deposition, whereas oral liquid suspensions and tablets provide versatility for outpatient management. Intravenous and intramuscular formulations remain indispensable in acute care settings. Patient type segmentation highlights the divergent needs of adult, geriatric, and pediatric populations, each group requiring tailored dosing regimens and safety considerations. Finally, distribution channels span hospital pharmacies, online pharmacies, and brick-and-mortar retail outlets, each pathway influencing product accessibility, pricing strategies, and patient engagement models.

Geography-Driven Differentiators in Respiratory Therapeutics

Regional dynamics significantly influence therapeutic adoption and market evolution. In the Americas, integrated healthcare systems in North America drive rapid uptake of advanced antivirals and biologics, supported by robust reimbursement frameworks, while Latin American markets prioritize cost-effective generics and broad-spectrum antibiotics due to resource constraints. Across Europe, Middle East, and Africa, diverse regulatory regimes and economic profiles create a mosaic of access challenges; Western Europe leads in precision diagnostics and antimicrobial stewardship initiatives, while emerging markets in the Middle East and Africa focus on expanding basic treatment coverage and overcoming logistical barriers. In the Asia-Pacific region, high population density and varied healthcare infrastructure accelerate demand for scalable inhalation therapies and oral formulations, with key economies investing heavily in domestic R&D hubs to reduce reliance on imports. These regional contrasts underscore the importance of localized strategies that align with regulatory environments, payer structures, and patient behavior patterns.

Competitive Landscape and Leading Innovators

The competitive arena features established pharmaceutical giants alongside nimble biotechnology firms pushing the frontier of respiratory therapeutics. Leading innovators have forged strategic alliances to co-develop next-generation antivirals, leveraging complementary expertise in virology and medicinal chemistry. Several multinational corporations have expanded their respiratory portfolios through targeted acquisitions, integrating specialty inhalation platforms and digital adherence tools into their offerings. Meanwhile, emerging players capitalize on orphan drug designations and accelerated regulatory pathways to fast-track novel anti-inflammatory agents. Competitive positioning increasingly hinges on demonstrating real-world effectiveness through post-launch evidence generation, as well as securing supply chain resilience. Across the board, intellectual property management and patent lifecycles shape launch timing and generic erosion risks, compelling companies to invest in lifecycle extension strategies and combination therapies that fortify market share.

Strategic Imperatives to Navigate Market Opportunities

Industry leaders must adopt multi-pronged tactics to secure sustainable growth. Prioritizing investment in precision medicine platforms and biomarker-driven clinical trials can yield differentiated therapies with superior efficacy and safety profiles. Strengthening supply chain agility through regional manufacturing hubs and strategic inventory buffers will mitigate exposure to future trade disruptions. Embracing digital therapeutics and remote patient monitoring solutions enhances treatment adherence and generates real-world data that inform value-based contracting. Collaborative partnerships with payers and policymakers can facilitate reimbursement for innovative treatments while supporting stewardship programs to curb resistance trends. Companies should also explore novel pricing models, such as outcome-based agreements, to align product value with healthcare system priorities. By integrating these strategic imperatives, organizations can navigate competitive pressures and capture emerging opportunities in respiratory infection management.

Rigorous Research Framework Ensuring Valid Insights

This analysis synthesizes qualitative and quantitative evidence drawn from comprehensive secondary research, structured interviews with clinical experts, and executive discussions across leading pharmaceutical and biotechnology organizations. Primary research encompassed input from key opinion leaders in pulmonology, infectious disease, and pharmacy practice, ensuring clinical relevance and market applicability. Data triangulation techniques validated insights against industry reports, regulatory filings, and patent databases. Competitive intelligence incorporated company financial filings, M&A transactions, and pipeline assessments. Segmentation and regional analyses were informed by detailed product registries, reimbursement frameworks, and healthcare utilization metrics. This rigorous framework underpins the report’s credibility, providing stakeholders with robust, actionable insights.

Synthesis of Key Findings and Future Outlook

In summary, the respiratory tract infection therapeutic market is at a pivotal juncture, shaped by technological innovation, regulatory recalibration, and evolving patient expectations. Tariff-induced supply chain realignments, coupled with dynamic regional requirements and sophisticated segmentation landscapes, create both challenges and avenues for growth. Competitive strategies grounded in precision medicine, digital integration, and resilient manufacturing will define the next wave of market leaders. Armed with granular insights into therapeutic categories, regional nuances, and corporate strategies, decision-makers are well positioned to chart successful paths forward. The insights presented herein illuminate the complex interplay of forces driving the market and highlight strategic inflection points essential for sustainable success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Type
    • Antibiotics
      • Fluoroquinolones
      • Macrolides
      • Penicillins
      • Tetracyclines
    • Antivirals
    • Cough Suppressants
    • Nasal Decongestants
    • Non-Steroidal Anti-Inflammatory Drugs
  • Infection Type
    • Lower Respiratory Tract Infection
      • Bronchitis
      • Pneumonia
      • Tuberculosis
    • Upper Respiratory Tract Infection
      • Laryngitis
      • Pharyngitis
      • Tonsillitis
  • Route Of Administration
    • Inhalation
      • Metered Dose Inhalers
      • Nebulizers
    • Oral
      • Liquid Suspensions
      • Tablets
    • Parenteral
  • Patient Type
    • Adults
    • Geriatrics
    • Pediatrics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • AdvaCare Pharma
  • Alkem Laboratories Limited
  • APPLIED BIOCODE, INC.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Inflammatix, Inc
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Novartis International AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi S.A.
  • Steris Healthcare Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Verona Pharma plc
  • ZAMBON COMPANY S.P.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Tract Infection Therapeutic Market, by Therapeutic Type
8.1. Introduction
8.2. Antibiotics
8.2.1. Fluoroquinolones
8.2.2. Macrolides
8.2.3. Penicillins
8.2.4. Tetracyclines
8.3. Antivirals
8.4. Cough Suppressants
8.5. Nasal Decongestants
8.6. Non-Steroidal Anti-Inflammatory Drugs
9. Respiratory Tract Infection Therapeutic Market, by Infection Type
9.1. Introduction
9.2. Lower Respiratory Tract Infection
9.2.1. Bronchitis
9.2.2. Pneumonia
9.2.3. Tuberculosis
9.3. Upper Respiratory Tract Infection
9.3.1. Laryngitis
9.3.2. Pharyngitis
9.3.3. Tonsillitis
10. Respiratory Tract Infection Therapeutic Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.2.1. Metered Dose Inhalers
10.2.2. Nebulizers
10.3. Oral
10.3.1. Liquid Suspensions
10.3.2. Tablets
10.4. Parenteral
11. Respiratory Tract Infection Therapeutic Market, by Patient Type
11.1. Introduction
11.2. Adults
11.3. Geriatrics
11.4. Pediatrics
12. Respiratory Tract Infection Therapeutic Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Respiratory Tract Infection Therapeutic Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Respiratory Tract Infection Therapeutic Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. AdvaCare Pharma
16.3.3. Alkem Laboratories Limited
16.3.4. APPLIED BIOCODE, INC.
16.3.5. AstraZeneca PLC
16.3.6. Boehringer Ingelheim GmbH
16.3.7. Cadila Healthcare Limited
16.3.8. Cipla Limited
16.3.9. F. Hoffmann-La Roche AG
16.3.10. GlaxoSmithKline plc
16.3.11. Glenmark Pharmaceuticals Limited
16.3.12. Hikma Pharmaceuticals PLC
16.3.13. Inflammatix, Inc
16.3.14. Intas Pharmaceuticals Limited
16.3.15. Lupin Limited
16.3.16. Merck & Co., Inc.
16.3.17. Mylan Inc. by Viatris Inc.
16.3.18. Novartis International AG
16.3.19. Perrigo Company PLC
16.3.20. Pfizer Inc.
16.3.21. Sanofi S.A.
16.3.22. Steris Healthcare Pvt. Ltd.
16.3.23. Teva Pharmaceutical Industries Ltd
16.3.24. Verona Pharma plc
16.3.25. ZAMBON COMPANY S.P.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LARYNGITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PHARYNGITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TONSILLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LIQUID SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 68. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 70. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 71. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 72. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 73. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 76. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 132. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 136. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 142. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 161. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 163. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 164. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 167. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 172. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 176. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 212. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 213. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 216. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 217. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 230. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 231. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 232. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 233. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 234. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 236. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 237. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 242. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 243. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 246. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 247. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 272. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2030 (USD MILLION)
TABLE 273. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARK

Companies Mentioned

The companies profiled in this Respiratory Tract Infection Therapeutic market report include:
  • Abbott Laboratories
  • AdvaCare Pharma
  • Alkem Laboratories Limited
  • APPLIED BIOCODE, INC.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Inflammatix, Inc
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Novartis International AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi S.A.
  • Steris Healthcare Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Verona Pharma plc
  • ZAMBON COMPANY S.P.A.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 51.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 73.64 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Lower Respiratory Tract Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Lower Respiratory Tract Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Cephalexin Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Cephalexin Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Anti-infectives Market by Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Anti-infectives Market by Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Azithromycin Market by Product Type, Dosage Form, Route Of Administration, Indication, End User, Sales Channel - Global Forecast to 2030 - Product Image

Azithromycin Market by Product Type, Dosage Form, Route Of Administration, Indication, End User, Sales Channel - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Non-cystic Fibrosis Bronchiectasis - Pipeline Insight, 2025 - Product Image

Non-cystic Fibrosis Bronchiectasis - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Respiratory Tract Infection Drug Market

The Respiratory Tract Infection Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat infections of the respiratory tract, such as bronchitis, pneumonia, and sinusitis. These drugs are typically antibiotics, antivirals, and anti-inflammatory medications. They are used to reduce symptoms, prevent complications, and reduce the spread of infection. The Respiratory Tract Infection Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson. Other companies include AbbVie, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.